Laboratory and clinical studies on temafloxacin

• Published in: CHEMOTHERAPY Vol. 41; no. Supplement5; pp. 799 - 807
• Main Authors: Yasunaga, Kojiro, Yamanaka, Yoshitaka, Yonezu, Seibun
• Format: Journal Article
• Language: English; Japanese
• Published: Japanese Society of Chemotherapy 1993; 公益社団法人 日本化学療法学会
• Subjects: temafloxacin; ニューキノロン系合成抗菌剤; 抗菌力; 臨床的検討
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.41.Supplement5_799

We studied temafloxacin (TMFX), a newly synthesized antibacterial agent which is a pyridonecarboxylic acid derivative, for its antibacterial activity in vitro and its clinical availability. The following results were obtained; 1) Antibacterial activity in vitro The MICs of TMFX against bacterial strains isolated from clinical foci were determined, and compared with those of ofloxacin (OFLX), ciprofloxacin (CPFX) and tosufloxacin (TFLX). The activity of TMFX against methicillin-susceptible and -resistant Staphylococcus aureus was superior to that of OFLX and CPFX, but inferior to that of TFLX. Against Escherichia coli, Klebsiella pneumoniae, Providencia rettgeri, Pseudomonas aeruginosa and Serratia marcescens, the antibacterial activity of TMFX was similar to that of OFLX, but inferior to that of CPFX and TFLX. However, against Proteus mirabilis and Morganella morganii, the activity of TMFX was lower than that of the other agents. 2) Clinical trial The patients were treated with.TMFX (150-300mg/day) for 4-14 days. One of the cases was excluded from the efficacy assessment. Of the remaining 38 cases (32 of RTI, 5 of UTI and 1 of skin infection), 34 responded to the therapy. Laboratory examination, carried out in 30 of 39 cases, revealed eosinophilia and elevations of ALP and γ-GTP in two patients each. Side effects were observed in two cases: diarrhea in one patient and fever in another.